Home › Funds › Redmile Group, LLC › BEAM
Redmile Group, LLC position in BEAM
BEAM THERAPEUTICS INC · Health Care
Redmile Group, LLC reported holding 1,164,259 shares of BEAM (BEAM THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$40.0M, representing 2.68% of its reported portfolio and ranking #11 among its reported holdings. Redmile Group, LLC has disclosed BEAM holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Redmile Group, LLC's BEAM position evolved
Redmile Group, LLC first disclosed a stake in BEAM in Q3 2023 at 1,469,725 shares (US$35.3M). The position peaked in Q1 2024 at 1,879,617 shares, worth US$62.1M. Across 12 filings, Redmile Group, LLC increased the stake 2 time(s), trimmed it 9 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 1,164,259 shares valued at US$40.0M — a reduction of -73,400 shares quarter over quarter.. Notable position changes include a 31% increase in Q1 2024 (shares fell 29% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 1.47M | $35.35M | New |
| Q4 2023 | 1.43M | $38.92M | Reduce |
| Q1 2024 | 1.88M | $62.10M | Add |
| Q2 2024 | 1.70M | $39.90M | Reduce |
| Q3 2024 | 1.61M | $39.47M | Reduce |
| Q4 2024 | 1.53M | $37.91M | Reduce |
| Q1 2025 | 1.61M | $31.45M | Add |
| Q2 2025 | 1.42M | $24.21M | Reduce |
| Q3 2025 | 1.39M | $33.68M | Reduce |
| Q4 2025 | 1.29M | $35.64M | Reduce |
| Q1 2026 | 1.24M | $29.49M | Reduce |
| Q2 2026 | 1.16M | $39.96M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BEAM and 13F data
BEAM (BEAM THERAPEUTICS INC) is a Health Care company. 34 other funds we track also report a position in BEAM — the largest reported positions include Farallon Capital Management (US$351.3M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$351.3M), ARK Invest (US$351.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BEAM
- Farallon Capital Management 10.24M sh · $351.31M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 10.24M sh · $351.31M · Q2 2026
- ARK Invest 10.23M sh · $351.26M · Q2 2026
- ARCH Venture Management, LLC 4.54M sh · $155.77M · Q2 2026
- Amova Asset Management Americas, Inc. 3.46M sh · $118.54M · Q2 2026
- Kynam Capital Management, LP 2.84M sh · $97.50M · Q2 2026
- Contrarius Group Holdings Ltd 1.61M sh · $55.41M · Q2 2026
- Casdin Capital 1.35M sh · $46.33M · Q2 2026
- Deep Track Capital, LP 1.00M sh · $34.32M · Q2 2026
More on Redmile Group, LLC
FAQ
How long has Redmile Group, LLC held BEAM?
Redmile Group, LLC has disclosed BEAM holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is Redmile Group, LLC's current position in BEAM?
As of Q2 2026, Redmile Group, LLC holds 1.16M shares of BEAM (BEAM THERAPEUTICS INC), valued at $39.96M, representing 2.68% of its reported portfolio and ranking #11.
Has Redmile Group, LLC been buying or selling BEAM?
In the latest 13F filing (Q2 2026), Redmile Group, LLC reduced its position in BEAM. The position peaked in Q1 2024 at 1.88M shares.
Which other funds hold BEAM?
Other major institutional holders of BEAM include Farallon Capital Management, FARALLON CAPITAL MANAGEMENT, L.L.C., ARK Invest, among 34 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.